Testing a new injection for severe skin itching and inflammation

Plain-English translation of NCT07711418 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called (NKTR-358) to see if it can help people with moderate-to-severe atopic dermatitis—a chronic skin condition that causes severe itching, redness, and inflammation. The study will compare this new medication to a placebo (a dummy treatment) to understand how well the medication works and whether it is safe.

Many people with moderate-to-severe atopic dermatitis do not respond well enough to creams and ointments alone, so researchers are testing this medication as an additional treatment option. This trial will help doctors understand if this new treatment can provide meaningful relief for patients who need stronger therapies.

Do you qualify?

You likely qualify if…

you are at least 12 years old and weigh at least 40 kg (about 88 pounds)
you have been diagnosed with atopic dermatitis for at least 12 months before joining
your atopic dermatitis is moderate to severe, affecting at least 10% of your skin and showing specific severity scores on standard medical scales
you have tried topical creams or ointments for your atopic dermatitis without good results, or you did not tolerate them well
you are willing to use effective birth control if you can become pregnant

You likely don't qualify if…

you have other active skin conditions or skin infections that need treatment
your atopic dermatitis has been unstable or unpredictable recently
you have experienced hives or urticaria in the past 4 weeks
you have previously taken similar immune-system medications (such as aldesleukin or JAK inhibitors) or other biologic drugs for any condition
you currently have an active infection or have had one recently

What participation looks like

You would receive injections of either the medication or a placebo every 2 weeks for an initial period, then the frequency would change to every 4 or 12 weeks during a maintenance phase. The entire study lasts approximately 15 months. You will have regular clinic visits to monitor how well the treatment is working and check for any side effects. If the medication isn't helping enough, you may be offered open-label treatment where everyone receives the active medication at doses determined by the research team.

AI-generated summary from trial data · Jul 20, 2026 · Not medical advice

Trial locations(1 site)

United States

Nektar Investigative Site, The Bronx, New York